Antibody-Drug Conjugate Manufacturing: Clinical Through Commercial ADC CDMO Services

Abzena support the robust scaling of ADC clinical through commercial manufacturing. We are dedicated to delivering excellence in quality, specializing in small molecule intermediates, including high-potency chemistry, payloads, linkers, and payload-linker chemical intermediates, as well as bioconjugation.

Abzena are focused on de-risking ADC manufacturing programs. Our key advantages are:

• Fully integrated end-to-end ADC manufacturing services and expertise
• cGMP-compliant facilities
• High-quality clinical through commercial support
• Specialized bioconjugation services with 20+ years of experience
• Seamless ADC technology transfer and strict adherence to all product quality requirements
• Aligned commercial bioconjugate manufacturing and process development facilities use advanced technologies to ensure efficient scale-up and minimize risk
• Quality first – to patients, regulatory authorities (FDA/EMA standards), and partners
• Recognized as a market‑leading ADC CDMO (Frost & Sullivan Radar Report, 2026)

Through 20+ years of bioconjugation experience and our deep scientific expertise in ADCs, we can offer a higher probability of clinical success and smoother IND progression.

Our scientific team has multiple decades of experience in ADC manufacturing and production. We have robust and refined processes that have proven to accelerate customer programs and move ADCs forwards into clinical and commercial manufacturing.

We understand that ADC manufacturing is a complex multi-step process which can be divided into three stages:

• cGMP production of the antibody
• cGMP synthesis of the drug-linker complex
• Conjugation to form an ADC

The conjugated antibodies then undergo extensive purification to remove therapeutic impurities. These are finished as ADC products upon the completion of fill-finishing.

ADC manufacturing involves the production of antibody-drug conjugates through a multi-step process including antibody production, payload synthesis, linker chemistry, and conjugation. As a specialized ADC manufacturing CDMO, Abzena provides integrated capabilities across each stage, ensuring consistent product quality and scalable GMP manufacturing from clinical development to commercial supply.